Immutep Limited (YP1A) - Total Liabilities

Latest as of December 2025: €48.30 Million EUR ≈ $56.47 Million USD

Based on the latest financial reports, Immutep Limited (YP1A) has total liabilities worth €48.30 Million EUR (≈ $56.47 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Immutep Limited - Total Liabilities Trend (2017–2024)

This chart illustrates how Immutep Limited's total liabilities have evolved over time, based on quarterly financial data. See YP1A current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Immutep Limited Competitors by Total Liabilities

The table below lists competitors of Immutep Limited ranked by their total liabilities.

Company Country Total Liabilities
Aeon Motor Co Ltd
TWO:1599
Taiwan NT$731.58 Million
Agile Group Holdings Limited
F:A8P
Germany €153.51 Billion
Computacenter PLC
LSE:CCC
UK GBX2.20 Billion
Huvitz Co. Ltd
KQ:065510
Korea ₩113.72 Billion
POS Malaysia&Services Holdings Bhd
KLSE:4634
Malaysia RM1.60 Billion
Yesil Gayrimenkul Yatirim Ortakligi AS
IS:YGYO
Turkey TL7.54 Billion
Sarveshwar Foods Limited
NSE:SARVESHWAR
India Rs6.64 Billion
Gotland Rederi AB Series A
ST:GOTL-A
Sweden Skr1.36 Billion

Liability Composition Analysis (2017–2024)

This chart breaks down Immutep Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Immutep Limited market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.97 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.49 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.33 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Immutep Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Immutep Limited (2017–2024)

The table below shows the annual total liabilities of Immutep Limited from 2017 to 2024.

Year Total Liabilities Change
2024-06-30 €12.06 Million
≈ $14.10 Million
+9.82%
2023-06-30 €10.98 Million
≈ $12.84 Million
-6.66%
2022-06-30 €11.76 Million
≈ $13.75 Million
+34.30%
2021-06-30 €8.76 Million
≈ $10.24 Million
-34.13%
2020-06-30 €13.30 Million
≈ $15.55 Million
-17.68%
2019-06-30 €16.15 Million
≈ $18.89 Million
+19.86%
2018-06-30 €13.48 Million
≈ $15.76 Million
+59.84%
2017-06-30 €8.43 Million
≈ $9.86 Million
--

About Immutep Limited

F:YP1A Germany Biotechnology
Market Cap
$53.07 Million
€45.39 Million EUR
Market Cap Rank
#21742 Global
#1942 in Germany
Share Price
€0.31
Change (1 day)
+7.69%
52-Week Range
€0.24 - €2.64
All Time High
€4.52
About

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more